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Abstract: A series of eleven cymantrene- and cyrhetrene-nucleobase conjugates together 
with the hitherto unreported N7-isomer of the ferrocene-adenine conjugate have been 
synthesised and characterized. The synthetic approach involved a Michael addition reaction of 
in situ generated acryloylcymantrene, acryloylcyrhetrene and acryloylferrocene with 
canonical nucleobases, such as thymine, uracil and adenine, respectively. The mechanism of 
these reactions was investigated by means of density functional theory (DFT) calculations. 
The respective products were characterized by spectroscopic methods and by electrochemical 
measurements. The molecular structure of one cymantrene-adenine conjugate (5) in the solid 
state was determined by single-crystal X-ray structure analysis, confirming the N9-
substitution mode of the adenine moiety.  It was found that the molecule adopts a bent 
conformation with the adenine and cyclopentadienyl planes in almost perpendicular 
orientation.  The cymantrenyl nucleobases showed an irreversible redox behaviour which is 
associated with ligand exchange reactions of the radical cationic species. The newly 
synthesised compounds were also tested for their activity against the protozoan parasite 
Trypanosoma brucei and human myeloid leukaemia HL-60 cells. Some compounds showed 
promising antitrypanosomal activity while most of them were non-toxic to HL-60 cells. It was 
additionally found that cymantrene and cyrhetrene ketone nucleobases were more active than 
their alcohol congeners. These findings indicate the potential of cymantrene and cyrhetrene 
nucleobase conjugates as possible lead compounds for future antitrypanosomal drug 
development. 
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Introduction 
The significance of organometallic complexes in biological applications have increased 
over the last decade.[1] They have been profoundly examined as anticancer agents[2] and there 
is also a growing interest in their antibacterial[3] and antiparasitic[4] applications. Furthermore, 
organometallic complexes are utilized as probes for single-cell bioimaging[5] and as photo-
activated anticancer agents with potential use in photodynamic therapy (PDT)[6] and 
photoactivated chemotherapy (PACT).[7] 
Cyclopentadienyl manganese tricarbonyl (= cymantrene) and cyclopentadienyl rhenium 
tricarbonyl (= cyrhetrene) half-sandwich piano-stool-structured compounds have recently 
received much attention towards biological applications. This field has been extensively 
reviewed, providing numerous interesting examples.[1b-c,8]  Some recent biological 
applications of cymantrene and cyrhetrene include their use as redox-active building blocks in 
the synthesis of tamoxifen anticancer drug derivatives.[9] The anodic electrochemistry of such 
half-sandwich tamoxifen congeners was studied by combined cyclic voltammetry (= CV) and 
IR spectroelectrochemistry.[9] Furthermore, subcellular imaging of a cyrhetrenyl-tamoxifen 
derivative in human MDA-MB-231 cancer cells was recently achieved by using an advanced 
photothermally induced resonance technique.[10] Labelling of hormone steroids with a 
nonradioactive cyrhetrenyl moiety has significant impact on the design of 99mTc radionuclide 
contrast agents for positron emission tomography (= PET) and on the development of 186/188Re 
radiopharmaceuticals.[11] In addition, cyrhetrene–arylsulfonamide, –arylsulfamide and –
arylsulfamate compounds have been shown to inhibit human carbonic anhydrase (hCA) 
enzymes in the low nanomolar range.[12] X-ray crystal structure analysis of cyrhetrenyl 
inhibitor/hCAII-complexes confirmed binding of the inhibitor in the active site of the 
enzyme.[12] It was shown that the half-sandwich cyrhetrenyl group bound to the three active 
site amino acids solely via hydrophobic interactions.[12] Also, conjugation of cymantrenyl and 
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cyrhetrenyl groups to peptides became a fruitful strategy for obtaining compounds with 
significant cytotoxicity.[13,14] Specifically, it has been demonstrated that the attachment of the 
cymantrenyl entity to cell-penetrating peptides yields cytotoxic anticancer conjugates that 
show enhanced accumulation in the nucleus of cancer cells.[14]  Cymantrenyl and cyrhetrenyl 
groups have also been successfully utilized in the synthesis of a new generation of 
antibacterial agents.[15] They show a new mechanisms of activity[15b] and the half-sandwich 
group is often essential for the bactericidal effect.[15c] Therapeutic properties of cymantrene 
and cyrhetrene complexes against malaria, leishmaniasis and trypanosomiasis is another area 
of application for these compounds.[16] In this respect, cymantrenes and cyrhetrenes derived 
from 5-nitrofuran,[16b,c] 4-aminoquinolines[16d] and triazoles[16e] have been reported to display 
antitrypanosomal activity against Trypanosoma cruzi and T. brucei species. 
The above mentioned examples show that functionalization of cymantrene and cyrhetrene 
cores with adequately designed substituents can lead to molecules with highly specific bio-
logical function. Accordingly, herein we report the synthesis, structure, density functional 
theory calculations and electrochemistry of cymantrene- and cyrhetrene-nucleobases 
(nucleobase = uracil, thymine, adenine). In addition, the hitherto unreported N7-isomer of a 
ferrocene-adenine compound is also reported. 
Our interest in half-sandwich cymantrene and cyrhetrene-nucleobase compounds stems from 
the biological importance of closely related ferrocenyl-nucleobase conjugates.[17a] 
Representatives of ferrocene-nucleobase conjugates have been shown to exhibit significant 
anticancer[17b-d] and antibacterial[17d] activity. Within this contribution the antitrypanosomal 
activity of cymantrene- and cyrhetrene-nucleobases against T. brucei is reported along with 
their in vitro anticancer activity against human HL-60 cells. To the best of our knowledge this 
is the first report on cymantrenyl- and cyrhetrenyl-nucleobase conjugates and their properties. 
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Results and Discussion 
In the initial stage of our studies cymantrene-pyrimidines (pyrimidine = thymine (3) or 
uracil (4)), cymantrene-adenine (5) and cyrhetrene-pyrimidines (pyrimidine = thymine (6) or 
uracil (7)) were consecutively obtained in two steps according to Scheme 1. At first, 
chloropropionyl-cymantrene (1) and chloropropionyl-cyrhetrene (2) were prepared in a 
straightforward manner under common Friedel-Crafts reaction conditions.[18] The following 
step involved a Michael addition of the nucleobase group and an in situ generated 
acryloylcymantrene and acryloylcyrhetrene species.[17a,d] The two “acryloyl” Michael 
acceptors were formed from the chloropropionyls 1 and 2 in a dehydrohalogenation reaction. 
After appropriate workup, cymantrenes 3 - 5 were isolated as yellow solids in a yield of 89, 
64 or 60 % (Experimental Section), respectively. Cyrhetrenes 6 and 7 were isolated as 
colourless solids in good yields (Experimental Section).   
 
 
Scheme 1 Synthesis of 3 ̶ 7 (DCM = dichloromethane, DMF = dimethylformamide; (i) 3-
chloropropionyl chloride, AlCl3, DCM, ambient temperature, 5 h; (ii) Et3N, DMF, 75 
oC, 5 h). 
 
In extension to the synthetic methodology used in the preparation of 3–7, the reaction of 
chloropropionyl-ferrocene (8) with adenine was conducted (Scheme 2). This reaction afforded 
the known N9-isomer 9[19] in 27 % yield and the new N7-isomer 10 in a yield of 10 %. Both 
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ferrocene derivatives were obtained as air-stable orange solids. The formation of the two 
isomers 9 and 10 contrasted the sole formation of isomer 5 (Scheme 1). To explain this 
inconsistency, the mechanism of both reactions was comparatively examined by means of 
DFT calculations (see below). 
 
 
Scheme 2 Synthesis of 9 and 10 ((i) adenine, Et3N, DMF, 75 
oC, 4 h). 
 
 
In the following, compounds 3 ̶ 7 were reduced to furnish the corresponding alcohols 11 ̶ 14 
(Scheme 3). This transformation was achieved by treatment of 3 ̶ 7 with sodium 
tetrahydridoborate in tetrahydrofuran. 
 
Scheme 3 Synthesis of 11 ̶ 14 ((i) Na[BH4], THF, 1 h, ambient temperature, then water). 
After appropriate work-up, cymantrenyl alcohols 11 and 12 were isolated as yellow solids 
(ca. 55% yield), while the corresponding cyrhetrenes 13 and 14 were obtained as colourless 
solids in a yield of approximately 80 %. However, treatment of the cymantrenyl-adenine 5 
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with Na[BH4] in tetrahydrofuran failed to give alcohol 15. To overcome this, an alternative 
reducing agent was applied. Accordingly, treatment of 5 with Li[AlH4] afforded 
corresponding 15 as a yellow solid in a yield of 81 % (Scheme 4). 
 
Scheme 4 Synthesis of 15 and 16 (dppe = 1,2-bis(diphenylphosphino)ethane) ((i) Li[AlH4], 
THF, 8 min, ambient temperature, then methanol/water mixture of ratio 1:1 (v/v); (ii) dppe, 
hν, THF, 2 h, ambient temperature). 
 
In addition, CO ligand substitution in 15 was examined. Ligand exchange reactions of 
cymantrene compounds occur under photochemical reaction conditions.[20] It is typical that 
shorter times of irradiation results in the formation of mono-substituted species, while longer 
exposure times favour the formation of di-substituted products. In our case, a tetrahydrofuran 
solution of alcohol 15 and 1,2-bis(diphenylphosphino)ethane was photolysed with a 200 W 
high-pressure mercury lamp for 2 h to obtain 16 (Scheme 4). After appropriate workup, 
compound 16 was isolated as an orange solid in a yield of 37 %. 
The identity of 1 ̶ 7 and 9 ̶16 was confirmed by NMR (1H, 13C) and IR spectroscopy, mass 
spectrometry, and elemental analysis. The analytical data confirm the proposed structures. In 
addition, the structure of 5 in the solid-state was determined by single-crystal X-ray 
crystallography. 
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Crystal structure 
Single crystals of 5 suitable for X-ray diffraction analysis were obtained by slow diffusion 
of hexane into a dichloromethane solution of 5. The oak ridge thermal-ellipsoid plot (ORTEP) 
drawing with the atom labelling scheme is shown in Figure 1, together with selected bond 
lengths and angles. Crystal and structure refinement data are attached in the ESI (Table S1). 
 
 
Figure 1 ORTEP diagram of 5 at 50% probability level; Mp1 and Mp2 correspond to mid-
points of the respective rings. Hydrogen atoms have been omitted for clarity. Selected bond 
lengths (Å) and angles (o): Mn1-Mp1, 1.764(3); O20-Mp2, 3.19(2); Mn1-C13, 2.124(2); 
Mn1-C14, 2.143(2); Mn1-C22, 1.791(2); Mn1-C20, 1.805(2); O20-C20; 1.143(2); C12-C13, 
1.477(2); C12-O1, 1.221(2); C10-N9, 1.451(2); N1-C6, 1.356(2); C13-C12-C11-C10, 
152.4(2); C12-C11-C10-N9, -74.4(2); C11-C10-N9-C8, 106.8(2); C20-O20…Mp2, 128.7(2). 
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The X-ray crystal structure analysis confirmed that the cymantrenyl moiety binds to the 
N9-position (Figure 1) of the adenine nucleobase. The manganese atom Mn1 is bonded to the 
cyclopentadienyl (Cp) group and to the three carbonyl groups in a typical three-legged piano-
stool fashion. The Mn-C(carbonyl) bond distances (1.805(2), 1.801(2), 1.791(2)) and Mn-
C(Cp) bond distances (2.124(2), 2.143(2), 2.152(2), 2.142(2), 2.129(2)) are close to that of 
known cymantrene derivatives.16d,e The carbonyl group of the hydrocarbyl linker is nearly 
coplanar with the Cp plane. Bond lengths and angels of the adenine group are unexceptional 
and need no further discussion. The most interesting feature of the crystal structure is the 
close spatial arrangement of the adenine and the cymantrenyl group linked by the hydrocarbyl 
chain. Accordingly, the plane of the adenine and the cyclopentadienyl group are almost 
perpendicular with a dihedral angle equal to 87.4(2). This molecular conformation is 
stabilized by intramolecular contact between the oxygen carbonyl atom O20 and the adenine 
ring. The O20…Mp2 distance is equal to 3.19(2) Å and the corresponding C20-O20…Mp2 
angle is 128.7(2)  (Mp2 is the mid-point of the six-membered ring of the adenine group). The 
absolute value of the dihedral angle between the adenine and the cymantrenyl groups along 
the C10-C11 bond is 74.4(2)o. Details of intermolecular interactions in the crystal structure of 
5 are given in SI (Table S2, Figs. S16, S17).  
 
DFT calculations 
Steric and electronic effects have been considered computationally to rationalize the 
experimental finding that both N9- and N7-isomers (9 and 10) have been isolated in the 
reaction of adenine with chloropropionyl-ferrocene 8, while in the reaction of adenine with 
chloropropionyl-cymantrene 1 only the N9-isomer 5 was formed. The observed 
regioselectivity has been interpreted in terms of thermodynamic and kinetic control of the 
reaction. 
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Steric Effects. A large difference in relative energies was calculated for the N7- and N9-
substituted adenines (Table S3; ESI and Scheme 5). The substitution in adenine at the N7-
position is attributed with an unfavorable steric repulsion between the N7-substituent and the 
amino group at C6 position, making the N9-isomers thermodynamically more stable. A minor 
stabilization of the N7-isomer in 10 can be explained by the more favorable interaction 
between the amine N-H bond and the carbonyl oxygen atom, which preferentially stabilizes 
the N7-isomer (Figure 3). 
 
Figure 3 The most stable conformations of 5, 9 and 10 formed in the Michael addition of 
adenine to chloropropionyl-cymantrene (formation of 5) and adenine to chloropropionyl-
ferrocene (9 and 10) optimized at the B3LYP/6-31+G(d) level of theory. The H bonding 
between the amine hydrogen and carbonyl oxygen is indicated by the dashed line. 
 
 
Kinetic vs thermodynamic control of the Michael reactions. Steric effects in N7- and N9-
substituted compounds are not sufficiently enough to explain the observed regioselectivity in 
the reaction between adenine with 1 and 8. If the reaction is thermodynamically driven, the 
N9-isomer would result as the only product (Table S3). However, our product analysis 
suggests that other issues than thermodynamic product stability should be considered. To 
rationalize the experimental observation, the kinetic competition between the two reactions 
was evaluated by means of DFT calculations. 
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Acryloylferrocene. The nucleophilic reaction between the adenine anion follows the classic β-
addition reaction, i.e., 1,4-conjugate addition. The adenine anion is an ambident nucleophile 
and can react at the N7- or N9-position. The corresponding transition state structures TS-N7Fc 
and TS-N9Fc (Figure 4) for the two parallel processes have been located and compared in 
energy (Scheme 5). It was found that the Michael addition which involves the N7-reactive 
center is the kinetically preferred process. The calculated barrier (ΔG‡ = 101.1 kJ/mol) is with 
4.7 kJ/mol lower than the barrier for the process in which the N9-nitrogen atom acts as a 
nucleophile. According to the transition state theory this energy barrier difference corresponds 
to the calculated ratio of rate constants kN7/kN9 ≈ 5. Therefore, the N7-product 10 is somewhat 
faster formed, yet the N9-product 9 is much more thermodynamically stable. This explains the 
experimental yield proportion of 9 to 10 of ca. 3. 
 
 
Figure 4. B3LYP/6-31+G(d) optimized transition state structures for the Michael addition 
reaction of the adenine anion to acryloylferrocene (formation of TS-N7Fc and TS-N9Fc) and to 
acryloylcymantrene (TS-N7Cym and TS-N9Cym). All distances are in Ångstrom. 
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Both transition structures TS-N7Fc and TS-N9Fc are characterized by the s-cis orientation 
of the acryloyl fragment and by imaginary frequencies (196i and 199i cm-1, respectively) 
which correspond to N-C bond formation concomitant with the enolization of the acryloyl 
moiety. It is interesting to note that the N7-reactive center in TS-N7Fc approaches the acryloyl 
ferrocene in an endo fashion, whereas the exo attack is favored in TS-N9Fc. The preference of 
the N7 attack (vs. N9) is likely due to intermolecular CO...HN hydrogen bond formation in 
TS-N7Fc. 
 
 
Scheme 5 Free energy profile (calculated at the CPCM-B3LYP/6-31+G(d) level) for two 
Michael addition reactions in which N7 and N9 products are formed. The energies of the 
reactant pairs of adenine anion/acryloylcymantrene and adenine anion/acryloylferrocene are 
arbitrarily set to zero for comparative purposes. The stationary points between the transition 
states and the final products correspond to enolate intermediates, as evidenced by the IRC 
procedure. 
 
Acryloylcymantrene. In case of the acryloylcymantrene, two Michael addition reactions are 
possible, but only the reaction at the N9-position seems most likely, since the N9-isomer was 
isolated as main product. Transition state structures for the two reactions are very similar in 
energy (ΔΔG‡ = 0.4 kJ/mol), which suggests that the exclusive formation of 5 is not under 
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kinetic control (Scheme 5). Transition states TS-N7Cym and TS-N9Cym are very similar to the 
structures of TS-N7Fc and TS-N9Fc, except the adjacent organometallic parts are different 
(Figure 4). The reaction follows the mechanism described for the ferrocene system, i.e. the 
adenine anion reacts with the acryloylcymantrene in a one-step process in which the N-C 
bond is formed simultaneously with enolization of the acryloyl system. 
For the reaction of acryloylcymantrene with the adenine anion, the calculated barriers are 10-
14 kJ/mol lower in energy than the barriers for the respective processes in acryloylferrocene. 
This suggests that acryloylcymantrene is more reactive as a Michael acceptor and hence the 
kinetic control of the addition reactions is less important. At 75 °C, the two energy barriers 
(ca. 90 kJ/mol) are both surmountable. Under the experimental conditions employed, the 
thermodynamic reaction control prevails and the more stable isomer 5 is formed as the main 
product. Additional support for the higher reactivity of acryloylcymantrene comes from the 
frontier molecular orbital analysis (Figure S19). The calculated energy gap between the 
HOMO (adenine as a nucleophile) and the LUMO (Michael acceptor) is smaller for the 
acryloylcymantrene. This suggests that the reaction between adenine and acryloylcymantrene 
should be faster than the corresponding reaction with acryloylferrocene.  
Electrochemistry 
The electrochemical measurements of 1, 3, 5, 9, 11 and 15 were carried out under an 
atmosphere of argon in anhydrous dichloromethane (1, 3, 5, 9, 11, 15), tetrahydrofuran (5) 
and acetonitrile (5) solutions, containing weakly coordinating [Bu4N][B(C6F5)4]
[21] (0.1 M) as 
the supporting electrolyte. The cyclic voltammetry measurements were recorded at scan rates 
varying between 50 mV·s-1 and 200 mV·s-1. All redox potentials are referenced against the 
FcH/FcH+ redox couple (E°′ = 0.00 V) as recommended by IUPAC (FcH = Fe(η5C5H5)2).[22] 
The benefit of using [B(C6F5)4]
– for the generation of cymantrene-based cationic oxidation 
products was recently reported.[23,24] Table 1 summarizes the respective electrochemical data. 
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The corresponding cyclic voltammograms (= CV) for 1, 3, 5, 9, 11 and 15 are shown in 
Figures 5 and S19-S22 (ESI). 
 
 
Table 1. Voltammetric data for compounds 1, 3, 5, 9, 11 and 15.a  
Compound Epa [mV]b Epc [mV]c ipc/ipa 
1 1195 - - 
3 1180 - - 
5 975 - - 
9 
365d 
1415 
305d 
- 
0.92 
- 
11 910 820 0.58 
15 
855 
975 
- 
905 
- 
0.41 
aPotentials vs FcH/FcH+; scan rate 100 mV·s−1; glassy-carbon electrode of 1.0 mmol·L−1 
solutions of the analytes in anhydrous dichloromethane containing 0.1 mol·L−1 of 
[NnBu4][B(C6F5)4] as supporting electrolyte at 25 °C. 
bEpc = cathodic peak potential. 
cEpa = 
anodic peak potential. dFormal Potential E°ʹ = 335 mV. 
 
Compounds 1, 3, 5, 9, 11 and 15 exhibit diffusion controlled anodic oxidations, except 9 
which shows an almost reversible process at 335 mV (ipc/ipa = 0.91) and an irreversible second 
oxidation at 1415 mV. Exemplary, the influence of the solvent on the oxidation process of the 
cymantrene compounds was studied using thymine derivative 5. It was found that in 
tetrahydrofuran and acetonitrile, respectively, irreversible electrode reactions took place 
(Figure S19). In acetonitrile, additional follow-up reactions of mono-oxidized 5+ were 
observed, most probably attributed to a substitution of one carbonyl ligand by a solvent 
molecule.[24] However, changing the solvent to less nucleophilic dichloromethane resulted in a 
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more stable current and an irreversible event was observed for 5 at Epa = 975 mV (Figure 5). 
Also for the adenine derivative 3 only one irreversible oxidation process at Epa = 1180 mV 
was observed in dichloromethane solution (Figure 5). The higher redox potential of 3, as 
compared to 5, substantiates higher electron withdrawing ability of the thymine group in 
comparison to the adenine one. However, for both compounds a rapid filming of the working 
electrode was observed after several cycles. Cymantrene alcohols 11 and 15 show a different 
redox behavior in comparison to 3 and 5. For 11 there is one oxidation process found at Epa = 
910 mV and one reduction event at Epc = 820 mV while for 15 two oxidations at Epa = 855 
mV and Epa = 975 mV and one reduction at Epc = 905 mV (Figure 5) are present. The second 
oxidation process is presumably due to oxidation of side products generated upon the first 
oxidation. The latter electrode reactions are shifted to more cathodic potentials, when 
compared to 3 and 5, due to a less electron-withdrawing of the hydroxyl functionality in α-
position. Furthermore, the trend that the thymine substituent shifts the redox process to more 
cathodic potentials is also typical for these species. As reported by Geiger et al., the 
cymantrene mono-cations become more stable against substitution of one carbonyl ligand as 
the electronic-donating character of the cyclopentadienyl ligand increases.[24] This is the 
reason why 11 and 15 shows a reduction process and 3 and 5 not. Exemplary, CV 
measurements at lower temperatures (0 °C, -20 °C) were performed for 15, but no increase of 
reversibility was observed. 
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Figure 5 Cyclic voltammograms of 1, 3, 5, 9, 11 and 15 (1.0 mmol·L), scan rate 100 mV·s 
at 25 °C, supporting electrolyte 0.1 mol·L [Bu4N][B(C6F5)4], working electrode: glassy 
carbon electrode (surface area 0.031 cm²). 
 
To gain more information on the redox-process of the molecule pattern, electrochemical 
measurements on 1 were performed, showing a similar behavior as 3 and 5, i.e. one 
irreversible oxidation process at Epa = 1195 mV (Figure 5). For investigating of the influence 
of nucleobases on the redox behavior and the deposition process, adenine was added (1 mmol 
L−1) to the analyte solution. The oxidation peak current ipa dropped with the numbers of 
cycles, thus the mixture of 3 and adenine behaved similar to compound 5 (Figure S20) in the 
electrochemical measurements. For further investigation on the substitution of carbonyl 
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ligands in the cymantrene molecule pattern, CV measurements on 9 were performed (Figure 
S21). A reversible redox process (E°′ = 335 mV) and an irreversible oxidation event (Epa = 
1415 mV) were observed. The irreversible oxidation process disappears after the first cycle, 
leading to a coating of the working electrode. However, the process associated with the 
ferrocenyl group is constant over several cycles. 
The CV measurements show that the cymantryl ketone cations 1+, 3+ and 5+ are unstable 
in solution. For the cymantryl aldehyde cation this behavior was reported before, indicating a 
fast carbonyl substitution with a nucleophile.[24] For 3+ and 5+ the adeninyl or uracilyl 
functionalities themselves could react as a nucleophile and undergo some intramolecular or 
intermolecular side reactions. The lower electron density at the metal, due to a lower electron 
donation capability of the cyclopentadienyl ligand, promotes the side reactions.[24] For 11 and 
15 a reduction process was found (Figure 5). A higher electron density at the metal (as 
compared to the cymantryl ketones) increases the metal ligand backbonding towards the 
carbonyl ligands and hence a slower substitution processes takes place.[24] The shift of the 
potential of both oxidation processes towards more cathodic potentials is a result of the higher 
electron density at Mn for 11+ and 15+. Therefore, it is possible, at least partially, to reduce 
the cymantryl alcohol cation. The uracil functionality possesses a less pronounced electron 
donation character, as compared with the adenine unit, and hence the oxidation processes are 
cathodic shifted for the corresponding ketones and alcohols, respectively. 
Bioactivity 
Antitrypanosomal and cytotoxic activity 
As cymantrene-triazole compounds have been previously shown to inhibit the growth of 
T. brucei[16e], we were interested whether the newly synthesised cymantrene and cyrhetrene 
nucleobase conjugates were also effective against this protozoan parasite. The trypanocidal 
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and cytotoxic activities of the cymantrene and cyrhetrene compounds were evaluated in vitro 
with T. brucei bloodstream forms 427-221a[25] and human myeloid leukaemia HL-60 cells[26] 
using the resazurin assay described previously.[27] Apart from compounds 13 and 14, all 
cymantrene and cyrhetrene nucleobase conjugates showed a dose-dependent effect on the 
growth of trypanosomes with MIC (minimum inhibitory concentration, i.e., the concentration 
of the compounds at which all cells were killed) values varying between 10 and >100 μM and 
GI50 (50% growth inhibition, i.e., the concentration of a compound necessary to reduce the 
growth rate of cells by 50% to that of controls) values ranging from 0.38 to 80.5 μM (Table 
2). 
 
Table 2. The in vitro antitrypanosomal and cytotoxic activity of cymantrene, cyrhetrene, 
suramin and compounds 1-16 against T. brucei and human myeloid leukaemia HL-60 cells. 
 T. brucei HL-60 Selectivity 
Compound. MIC (μM) GI50 (μM)a MIC (μM) GI50 (μM)a MIC 
ratio 
GI50 
ratio 
Cym 100 44.6±12.3 >100 >100 (0%) >1 >2.2 
Cyr >100 >100 (9%) >100 >100 (3%) 1 1 
1 10 0.38±0.01 100 29.6±10.1 10 77.9 
2 10 2.73±0.04 100 29.6±2.6 10 10.8 
3 10 4.41±1.02 >100 >100 (3%) >10 >22.7 
4 100 3.60±0.66 >100 >100 (22%) >1 >27.8 
5 >100 59.6±11.1 >100 >100 (6%) 1 >1.7 
6 10 3.36±0.39 >100 >100 (0%) >10 >29.8 
7 10 3.55±0.13 >100 >100 (0%) >10 >28.2 
9 100 18.2±5.5 >100 >100 (12%) >1 >5.5 
10 100 20.5±5.3 >100 >100 (0%) >1 >4.9 
11 100 38.8±8.9 >100 >100 (3%) >1 >2.6 
12 >100 80.5±24.7 >100 >100 (0%) 1 >1.2 
13 >100 >100 (33%) >100 >100 (0%) 1 1 
14 >100 >100 (19%) >100 >100 (0%) 1 1 
15 >100 30.8±3.5 >100 >100 (2%) 1 >3.2 
16 10 1.67±0.37 100 21.8±8.6 10 13.1 
Suramin 0.1-1 0.039±0.003 >100 >100 (4%) >1000-
100 
>2564 
a Values in brackets are the growth inhibition at 100 μM. 
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In most cases, the nucleobase conjugates were more active than the parent compounds 
cymantrene and cyrhetrene. The thymine and uracil conjugates 3, 4, 6 and 7 displayed similar 
trypanocidal activity with GI50 values of around 4 μM, while their corresponding alcohols 11, 
12, 13 and 14 were much less active. Cymantrene and ferrocene adenine conjugates 5, 15, 9, 
and 10 were also less effective. Interestingly, the chloropropionyl compounds 1 and 2 used in 
the synthesis of cymantrene and cyrhetrene nucleobase conjugates exhibited higher 
trypanocidal activity, which is probably due to their alkylating reactivity. Notably, 
replacement of the chlorine atom in 1 and 2 by nucleobases resulted in compounds with no 
cytotoxicity against human cells, while their trypanocidal activity of their thymine and uracil 
conjugates was reduced 1.3-fold (cyrhetrene conjugates 6 and 7) and 10-fold (cymantrene 
conjugates 3 and 4), respectively.  Also the cymantrene-dppe derivative 16 showed increased 
antitrypanosomal activity. With the exception of 1, 2 and 16, all other compounds were 
nontoxic to HL-60 cells (Table 2). This is an important finding as one crucial criteria for the 
development of new trypanocidal drugs is the absence of toxicity to mammalian cells. Despite 
the lack of cytotoxicity of cymantrene and cyrhetrene nucleobase conjugates, their MIC and 
GI50 ratios of cytotoxic to trypanocidal activities (selectivity indices) were found to be in an 
unfavourable to modest range (Table 2). For comparison, the reference drug suramin, one of 
the drugs used in the treatment of sleeping sickness, had a MIC ratio and a GI50 ratio of 
>1000-100 and >2000, respectively (Table 2). Nevertheless, cymantrene and cyrhetrene 
nucleobase conjugates are promising trypanocidal compounds that provide templates for 
further optimization to increase their antitrypanosomal activity. 
 
Conclusions 
Eleven cymantrene- and cyrhetrene-nucleobase conjugates have been synthesized and 
characterized. They represent the first examples of functionalized nucleobase cymantrene and 
cyrhetrene compounds. Furthermore, the synthesis of a hitherto unreported N7-isomer of a 
ferrocene-adenine conjugate is reported. The key step in synthesis of all compounds involved 
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an N1-regioselective Michael addition of the respective nucleobase nucleophile (a Michael 
donor) to an in situ generated organometallic acryloyl electrophile reagent (a Michael 
acceptor). The Michael addition reaction of acryloylferrocene with adenine afforded the N9-
adenine isomer along with the N7-isomer. In contrary, when acryloylcymantrene was reacted 
with adenine only the respective N9-adenine isomer was formed. DFT calculations show that 
the reaction of acryloylferrocene with adenine is kinetically controlled, while 
acryloylcymantrene reacts with adenine under thermodynamic control. A single crystal X-ray 
diffraction study of 5 revealed that the cymantrenyl moiety binds to the N9-position of the 
adenine nucleobase and that the plane of the adenine and the cyclopentadienyl group are 
almost perpendicular to each other. Electrochemical measurements on the cymantrenyl 
nucleobases showed irreversible behavior for all compounds presumably associated with a 
ligand exchange of carbonyls with the donor functionality of the nucleobases. These processes 
also caused a deposition at the electrode surface. 
The in vitro antitrypanosomal activity assay showed that cymantrene and cyrhetrene 
ketone nucleobases were more active than their corresponding alcohol derivatives. The 
substitution of the chlorine atom by nucleobase moieties in chloroketone cymantrene and 
cyrhetrene retain antitrypanosomal activity but eliminate undesired cytotoxic effect towards 
human cells.  Substitution of two CO ligands in the cymantrene framework by the phosphine 
ligand 1,2-bis(diphenylphosphino)ethane  led to an increase in antitrypanosomal activity. 
This, however, was associated with an increase in cytotoxic activity. The compounds 
synthesized in this study are amongst the most potent antitrypanosomal organometallics 
described to date. Further effort is undertaken in our lab to obtain more active derivatives. 
Experimental  
General: 
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All preparations were carried out using standard Schlenk techniques. Chromatographic 
separations were carried out using silica gel 60 (Merck, 230-400 mesh ASTM) and aluminium 
oxide (EcoChromTM MP Biomedicals). Dichloromethane, trimethylamine, dimethylform-
amide, and tetrahydrofuran were distilled and deoxygenated prior to use. Other solvents were 
of reagent grade and were used without prior purification. Thymine, uracil, adenine, 3-
chloropropionyl chloride, lithium aluminum hydride, sodium borohydride, aluminium 
chloride, and 1,2-bis(diphenylphosphino)ethane were purchased from commercial suppliers 
and were used without further purification. 1H NMR (600 MHz) and 13C{H} NMR (150 
MHz) spectra were recorded with a Bruker Avance III 600 spectrometer operating at 298 K in 
the Fourier transform mode. Chemical shifts are reported in  units (ppm) using residual 
DMSO (1H  2.50 ppm, 13C  39.70) as reference. Infrared spectra were recorded with an 
FTIR Nexus Nicolet apparatus. Mass spectra were recorded with a Varian 500-MS iT mass 
spectrometer (ESI) or with a Finnigan Mat95 mass spectrometer (EI). Microanalyses were 
determined by Analytical Services of the Polish Academy of the Sciences, Łódź. Purification 
of compound 16 was achieved by normal phase HPLC (Shimadzu Prominence with LC-20AP 
pumps) with Luna 5u Silica (2) 100A, AXIA Packed 150 X 21.1 mm preparative column. 
 
DFT and TD-DFT computations 
The quantum chemical calculations were performed using the Gaussian09 suite of 
programs.[28] All geometries were fully optimized at the B3LYP/6-31+G(d) level[29] in the gas 
phase and in the model solvent (DMF). The latter results are presented throughout the text 
(full details are listed in Table S4). The solvent effects on geometry optimization and 
solvation free energies (ΔGsolv) have been determined using the self-consistent reaction field 
(SCRF) method based on the polarizable conductor calculation model (CPCM).[30] The 
solvent relative permittivity of   = 37.219 (DMF) and electrostatic scaling (α) of 1.2 were 
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used. The united atom topological model (UA0) was applied on atomic radii of the UFF force 
field for heavy atoms. All energies are reported at 343.15 K in order to reproduce the 
experimental conditions. Thermal corrections to Gibbs free energies were calculated at the 
B3LYP/6-31+G(d) level using the rigid rotor/harmonic oscillator model, and were scaled by 
0.9806.[31] Analytical vibrational analyses at the corresponding level of theory were 
performed to characterize each stationary point as minimum (NImag = 0) or first-order saddle 
point (NImag = 1). Intrinsic reaction coordinate (IRC) calculations were performed at the 
corresponding level to identify the minima connected through the transition state. Improved 
energetics were calculated using B3LYP method with the augmented Wachters’ basis set on 
Fe and Mn,[32] and 6-311+G(d,p) basis set on all other atoms. 
Electrochemistry 
Electrochemical measurements on dichloromethane solutions containing 1.0 mmol·L-1 of 1, 
3, 5, 9, 11 or 15 were performed at 25 °C with a Radiometer Voltalab PGZ 100 
electrochemical workstation interfaced with a personal computer. Dichloromethane solutions 
(0.1 mol·L-1) containing [NBu4][B(C6F5)4]
[21] were used as supporting electrolyte. For the 
measurements a three electrode cell containing a Pt auxiliary electrode, a glassy carbon 
working electrode (surface area 0.031 cm²) and an Ag/Ag+ (0.01 mmol·L-1 [AgNO3]) 
reference electrode fixed on a Luggin capillary was applied. The working electrode was 
pretreated by polishing on a Buehler microcloth first with a 1 micron and then with a ¼ 
micron diamond paste. The reference electrode was constructed from a silver wire inserted 
into a 0.01 mmol·L-1 AgNO3 and 0.1 mol·L
-1 [NBu4][B(C6F5)4] acetonitrile solution in a 
Luggin capillary with a Vycor tip. This Luggin capillary was inserted into a second Luggin 
capillary containing a 0.1 mol·L-1 [NBu4][B(C6F5)4] dichloromethane solution and a Vycor 
tip. Experiments under the same conditions showed that all reduction and oxidation potentials 
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were reproducible within 5 mV. Experimental potentials were referenced against an Ag/Ag+ 
reference electrode but the presented results are referenced against ferrocene as an internal 
standard as required by IUPAC.[22] To achieve this, each experiment was repeated in the 
presence of 1 mmol·L-1 decamethylferrocene (= Fc*). Data were processed on a Microsoft 
Excel worksheet to set the formal reduction potentials of the FcH/FcH+ couple to 0.0 V. 
Under our conditions the Fc*/Fc*+ couple was at -619 mV vs FcH/FcH+ (Ep = 60 mV), 
while the FcH/FcH+ couple itself was at 220 mV vs Ag/Ag+ (Ep = 61 mV).[33] 
Antitrypanosomal and cytotoxicity assays 
Bloodstream forms of T. brucei clone 427-221a[25] and human myeloid leukaemia HL-60 
cells[26] were grown in Baltz medium[34] and RPMI medium[35], respectively. Both media were 
supplemented with 16.7% heat-inactivated foetal calf serum. All cultures were maintained at 
37 °C in a humidified atmosphere containing 5 % of CO2. Toxicity assays were performed as 
previously described.[27] In brief, trypanosomes and HL-60 cells were seeded at an initial cell 
density of 104 mL-1 and 105 mL-1, respectively, in 96-well plates in a final volume of 200 μL 
culture medium containing various concentrations of test compounds dissolved in 100 % 
DMSO. It should be noted that none of the test compounds formed precipitates when diluted 
with medium. The controls contained DMSO alone. In all experiments, the final DMSO 
concentration was 0.9 %. After 24 h incubation, 20 µl of a 0.44 mM resazurin solution 
prepared in PBS was added and the cultures were incubated for a further 48 h. Resazurin is a 
vital dye that, when being reduced by living cells, changes its colour from blue to pink. Thus, 
by measuring absorbance, the proliferation of cells can be easily determined. The change in 
absorbance was read on a microplate reader using a test wavelength of 570 nm and a 
reference wavelength of 630 nm. GI50 values were calculated by linear interpolation according 
to the method described by Huber and Koella.[36] MIC values were determined 
microscopically. 
 
Synthesis of chloropropionyl-cymantrene (1) 
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Cymantrene (500 mg, 2.45 mmol) dissolved in dichloromethane (25 mL) was treated with 
3-chloropropionyl chloride (234 μL, 2.45 mmol) and AlCl3 (327 mg, 2.45 mmol). After 5 h at 
ambient temperature, the reaction mixture was poured onto a 3% aqueous HCl solution. The 
resulting dichloromethane and water phases were separated. The dichloromethane phase was 
dried over MgSO4 and evaporated to dryness. The residue was dissolved in dichloromethane 
and subjected to column chromatography on SiO2 (eluent dichloromethane) to give compound 
1 as a yellow solid. Crystallization from dichloromethane-n-pentane at -78 oC afforded 1 as 
yellow crystals in a yield of 88 % (635 mg). 
1H NMR (600 MHz, DMSO-d6 ):  = 5.85 (pt, JH,H = 1.8 Hz,  2H, Cp), 5.21 (pt, JH,H = 1.8 Hz, 
2H, Cp), 3.84 (t, JH,H = 6.0 Hz, 2H, CH2), 3.16 (t, JH,H = 6.0 Hz, 2H, CH2). 
13C NMR (150 
MHz, DMSO-d6):  = 223.5, 194.3, 91.7, 87.9, 85.2, 41.0, 38.9. MS (EI, 70eV): m/z = 
294(M+), 238(M+-2CO), 210(M+-3CO). FTIR (KBr): 3129(CH), 3107(CH), 2987(CH), 
2968(CH), 2908(CH), 2027(CO), 1945(CO), 1926(CO), 1679(C=O), 1461, 1397, 1382, 1264 
cm-1. Anal. Calcd for C11H8O4ClMn: C, 44.85; H, 2.74%. Found: C, 44.90; H, 2.59%. 
 
Synthesis of chloropropionyl-cyrhetrene (2) 
Cyrhetrene (215 mg, 0.6 mmol) dissolved in dichloromethane (15 mL) was treated with 3-
chloropropionyl chloride (122 μL, 1.28 mmol) and AlCl3 (85 mg, 0.6 mmol). After 4 h of 
stirring at ambient temperature, the reaction mixture was poured onto a 3% aqueous HCl 
solution. The resulting dichloromethane and water phases were separated. The 
dichloromethane phase was dried over MgSO4 and evaporated to dryness. The residue was 
dissolved in chloroform and subjected to column chromatography on SiO2 (eluent 
chloroform) to give chloropropionyl-cyrhetrene 2 as a colourless solid. Crystallization from 
chloroform-n-pentane afforded the compound as colourless crystals in 76 % yield (425 mg). 
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1H NMR (600 MHz, DMSO-d6 ):  = 6.46 (pt, JH,H = 2.3 Hz, 2H, Cp), 5.80 (pt, JH,H = 2.3 Hz, 
2H, Cp), 3.84 (t, JH,H = 6.0 Hz, 2H, CH2), 3.16 (t, JH,H = 6.0 Hz, 2H, CH2). 
13C NMR (150 
MHz, DMSO-d6):  = 193.1, 192.2, 96.2, 89.6, 87.2, 40.8, 39.1. MS (ESI): m/z = 427(M+H+). 
FTIR (KBr): 3142(CH), 3120(CH), 3110(CH), 2956(CH), 2898(CH), 2034(CO), 1936(CO), 
1913(CO), 1676(C=O), 1461, 1369 cm-1. Anal. Calcd for C11H8O4ClRe: C, 31.03; H, 1.89% 
Found: C, 30.96; H, 1.83%. 
 
General procedure for the synthesis of cymantrene and cyrhetrene Michael adducts 3  ̶7 
To a stirred solution of the appropriate chloropropionyl-cymantrene (1.0 mmol) in DMF 
(15 mL) at ambient temperature 280 μL (2.0 mmol) of trimethylamine were added in a single 
portion. After stirring the reaction solution for 20 min, the appropriate nucleobase (1.0 mmol) 
was added and the mixture was stirred at a temperature of 75 oC for 5 h. Subsequently, the 
solvent was evaporated and the residue subjected to column chromatography on SiO2. 
Chromatographically purified complexes 3 ̶ 7 were crystallized to yield analytically pure 
products.  
Compound 3 Chromatography eluent: chloroform-methanol, 50/4 (v/v). Crystallization 
from dichloromethane-n-hexane gave 3 as a yellow solid in a yield of 89 % (342 mg). 
1H NMR (600 MHz, DMSO-d6 ):  = 11.18 (s, 1H, NH), 7.47 (s, 1H, H6 thymine), 5.81(pt, 
JH,H = 1.8 Hz,  2H, Cp), 5.20 (pt, JH,H = 1.8 Hz, 2H, Cp), 3.90 (t, 
3JH,H = 6.6 Hz, 2H, CH2), 
3.05 (t, 3JH,H = 6.6 Hz, 2H, CH2), 1.72 (s, 3H, CH3). 
13C NMR (150 MHz, DMSO-d6):  = 
223.4, 195.7, 164.3, 150.8, 141.8, 108.2, 91.6, 87.6, 85.3, 42.9, 37.5, 11.9. MS (EI, 70eV): 
m/z = 384(M+), 300(M+-3CO). FTIR (KBr): 2955(CH), 2925(CH), 2854(CH), 2027(CO), 
1939 (CO), 1674(C=O) cm-1. Anal. Calcd for C16H13N2O6Mn: C, 50.02 ; H, 3.41 ; N, 7.29%. 
Found: C, 50.09 ; H, 3.52 ; N, 7.08%. 
Compound 4 Chromatography eluent: chloroform-methanol, 50/2 (v/v). Crystallization 
from chloroform-n-hexane gave 4 as a yellow solid in a yield of 64 % (240 mg). 
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1H NMR (600 MHz, DMSO-d6 ):  = 11.18 (s, 1H, NH), 7.60 (d, JH,H = 7.8 Hz, 1H, H6 
uracil), 5.80 (pt, JH,H = 1.8 Hz, 2H, Cp), 5.50 (d, JH,H = 7.8 Hz, 1H, H5 uracil), 5.20 (pt, JH,H = 
1.8 Hz, 2H, Cp), 3.93 (t, 3JH,H = 6.6 Hz, 2H, CH2), 3.05 (t, 
3JH,H = 6.6 Hz, 2H, CH2). 
13C 
NMR (150 MHz, DMSO-d6):  = 223.3, 195.6, 163.6, 150.7, 146.0, 100.5, 91.5, 87.5, 85.2, 
43.1, 37.3. (EI, 70eV): m/z = 370(M+), 286(M+-3CO). FTIR (KBr): 3101(CH), 3048(CH), 
2968(CH), 2933(CH), 2029(CO), 1938(CO), 1676(C=O), 1459,1375, 1264 cm-1.  Anal. Calcd 
for C15H11N2O6Mn: C, 48.67 ; H, 3.00 ; N, 7.57%. Found: C, 48.95 ; H, 3.25 ; N, 7.33%. 
Compound 5 Chromatography eluent: chloroform-methanol, 50/4 (v/v). Crystallization 
from chloroform-n-hexane gave 5 as a yellow solid in a yield of 60 % (236 mg). 
1H NMR (600 MHz, DMSO-d6 ):  = 8.11 (s, 1H, H2 adenine), 8.04 (s, 1H, H8 adenine), 7.11 
(s, 2H, NH2), 5.79 (pt, JH,H = 1.8 Hz, 2H, Cp), 5.18 (pt, JH,H = 1.8 Hz,  2H, Cp), 4.42 (t, 
3JH,H 
= 6.6 Hz, 2H, CH2), 3.31 (t, 
3JH,H = 6.6 Hz, 2H, CH2). 
13C NMR (150 MHz, DMSO-d6):  = 
223.4, 195.4, 156.0, 152.4, 149.6, 141.2, 119.1, 91.5, 87.6, 85.2, 38.2, 38.0. MS (EI, 70eV): 
m/z = 393(M+), 365(M+-CO), 309(M+-2CO). FTIR (KBr): 3358(NH), 3160(NH), 2933(CH), 
2021(CO), 1948(CO), 1928(CO), 1675(C=O), 1654(C=O), 1596(NH), 1578(NH) cm-1. Anal. 
Calcd for C16H12N5O4Mn: C, 48.87 ; H, 3.08 ; N, 17.81%. Found: C, 48.79 ; H, 3.21 ; N, 
17.54%. 
Compound 6 Chromatography eluent: chloroform-methanol, 50/3 (v/v). Crystallization from 
chloroform-n-pentane gave 6 as a colourless solid in a yield of 58% (158 mg). 
1H NMR (600 MHz, DMSO-d6 ):  = 11.18 (s, 1H, NH), 7.45 (d, JH,H = 1.08 Hz, 1H, H6 
thymine), 6.43 (pt, JH,H = 2.34 Hz, 2H, Cp), 5.78 (pt, JH,H = 2.34 Hz, 2H, Cp), 3.90 (t, 
3JH,H = 
6.4 Hz, 2H, CH2), 3.06 (t, 
3JH,H = 6.4 Hz, 2H, CH2), 1.72 (d, JH,H = 0.9 Hz, 3H, CH3). 
13C 
NMR (150 MHz, DMSO-d6):  = 193.5, 193.0, 164.3, 150.8, 141.8, 108.2, 96.1, 89.4, 87.2, 
43.0, 37.3, 12.0. MS (EI, 70eV): m/z = 516(M+), 488(M+-CO), 460(M+-2CO). FTIR (KBr): 
3149(CH), 3108(CH), 3025(CH), 2930(CH), 2034 (CO), 1933(CO), 1904(CO), 1689(C=O), 
1673(C=O), 1467, 1457, 1364 cm-1. Anal. Calcd for C16H13N2O6Re: C, 37.28; H, 2.54; N, 
5.43%. Found: C, 37.48; H, 2.61; N, 5.42%. 
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Compound 7 Chromatography eluent: chloroform-methanol, 50/2 (v/v). Crystallization from 
chloroform-n-pentane gave 7 as a colourless solid in a yield of 63% (185 mg). 
1H NMR (600 MHz, DMSO-d6 ):  = 11.19 (bs, 1H, NH), 7.58 (d, JH,H = 7.8 Hz, 1H, H6 
uracil), 6.42 (pt, JH,H = 2.2 Hz, 2H, Cp), 5.79 (d, JH,H = 2.2 Hz, 2H, Cp), 5.50 (dd, JH,H = 7.8 
Hz, 2.0 Hz, 1H, H5 uracil), 3.93(t, 3JH,H = 6.4 Hz, 2H, CH2), 3.08 (t, 
3JH,H = 6.4 Hz, 2H, CH2). 
13C NMR (150 MHz, DMSO-d6):  = 193.5, 193.0, 163.7, 150.9, 146.1, 100.7, 96.1, 89.3, 
87.2, 43.3, 37.2. MS (ESI): m/z = 525(M+Na+). FTIR (KBr): 3104(CH), 3041(CH), 
2923(CH), 2027(CO), 1915(CO), 1910(CO), 1679(C=O), 1461, 1366 cm-1. Anal. Calcd for 
C15H11N2O6Re: C, 35.93; H, 2.21; N, 5.59% Found: C, 35.81; H, 2.37; N, 5.43%. 
 
Synthesis of ferrocenyl Michael adducts 9 and 10 
To a stirred solution of chloropropionyl-ferrocene (1000 mg, 3.6 mmol) in DMF (20 mL) 
trimethylamine (974 μL 7.0 mmol) was added in a single portion at ambient temperature. 
After 20 min of stirring, adenine (487 mg, 3.6 mmol) was added and the mixture was stirred 
at a temperature of 75 oC for 4 h. Subsequently, all volatiles were evaporated and the residue 
subjected to a preliminary column chromatography on SiO2 (eluent chloroform-methanol 50/5 
(v/v)) which afforded crude 9 and 10, respectively.  
Compound 9 was purified by a second column chromatography on deactivated Al2O3 
(Al2O3/H2O 36 g/1.25 g) using a chloroform-methanol mixture of ratio 50/5 (v/v) as eluent. 
After removal of the solvents, compound 9 was crystallized from a chloroform-n-hexane 
mixture of ratio 1/1 (v/v) to afford an analytically pure orange solid sample in a yield of 27 % 
(365 mg). 
Compound 10 was also purified by a second column chromatography on SiO2 with 
chloroform-methanol 50/5 (v/v) as eluent. Purified 10 was crystallized from a chloroform-n-
hexane mixture affording 10 as an orange solid in a 10% yield (135 mg). 
28 
 
Compound 9 1H NMR (600 MHz, DMSO-d6):  = 8.18 (s, 1H, H-2 adenine), 8.12 (s, 1H, H-
8 adenine), 7.13 (s, 2H, NH2), 4.78 (pt, JH,H = 1.8 Hz, 2H, C5H4), 4.55 (pt, JH,H = 1.8 Hz, 2H, 
C5H4), 4.47 (t, 
3JHH = 6.0 Hz, 2H, CH2), 3.98 (s, 5H, C5H5), 3.39 (t, 
3JHH = 6.0 Hz, 2H, CH2). 
13C NMR (150 MHz, CDCl3):  = 200.8, 156.0, 152.4, 149.5, 141.4, 118.9, 78.6, 72.4, 69.5, 
69.1, 38.5, 38.1. MS (EI, 70eV): m/z = 375(M+), 240(acryloyl ferrocene), 135(adenine). FTIR 
(KBr): 3432, 3270, 3105, 1664(CO), 1603(CO) cm-1. Anal. Calcd for C18H17N5OFe : C, 
57.62; H, 4.57; N, 18.67%. Found: C, 57.29 ; H, 4.46 ; N, 18.14%. 
Compound 10 1H NMR (600 MHz, DMSO-d6):  = 8.28 (s, 1H, H-8 adenine), 8.17 (s, 1H, 
H-2 adenine), 6.99 (s, 2H, NH2), 4.739 (pt, JH,H = 1.8 Hz, 2H, C5H4), 4.730 (t, 
3JHH = 6.0 Hz, 
2H, CH2), 4.55 (pt, JH,H = 1.8 Hz, 2H, C5H4), 3.95 (s, 5H, C5H5), 3.29 (t, 
3JHH = 6.0 Hz, 2H, 
CH2). 
13C NMR (150 MHz, CDCl3):  = 200.4, 160.2, 152.2, 151.7, 146.6, 111.1, 78.5, 72.4, 
69.5, 69.0, 41.2, 40.4. MS (EI, 70eV): m/z = 375(M+), 240(acryloyl ferrocene), 135(adenine). 
FTIR (KBr): 3385, 3180, 1648(CO), 1602(CO) cm-1. Anal. Calcd for C18H17N5OFe + n-
hexane: C, 62.48; H, 6.77; N, 15.18%. Found: C, 62.19; H, 6.14; N, 15.74%. 
 
General procedure for the synthesis of cymantrene alcohols 11 and 12 
To a stirred THF solution (25 mL) containing 3 or 4 (0.55 mmol) Na[BH4] (21 mg, 0.55 
mmol) was added in a single portion at ambient temperature. After 70 min of stirring, the 
reaction mixture was poured into 25 mL of water, extracted with chloroform (ca. 40 mL), 
dried over MgSO4 and the obtained solution was evaporated to dryness. The residue was 
subjected to column chromatography on SiO2 (eluent chloroform-methanol 50/1 (v/v)). 
Crystallization from dichloromethane-n-hexane gave alcohols 11 and 12 as yellow solids in a 
57% yield (120 mg) and 55% yield (111 mg), respectively.  
 Compound 11 1H NMR (600 MHz, DMSO-d6 ):  = 11.16 (s, 1H, NH), 7.46 (d, JH,H = 1.2 
Hz 1H, H6 thymine), 5.43 (d, 3JH,H = 5.4 Hz, 1H, OH), 5.08 (m, 1H, Cp), 5.06 (m, 1H, Cp), 
4.89 (m, 1H, Cp), 4.87 (m, 1H, Cp), 4.22 (m, 1H, CH), 3.81 (m, 1H, CH2), 3.67 (m, 1H, CH2), 
1.92 (m, 1H, CH2), 1.77 (m, 1H, CH2), 1.75 (d, JH,H = 0.6 Hz, 3H, CH3). 
13C NMR (150 MHz, 
DMSO-d6):  = 225.5, 164.3, 150.9, 141.6, 110.8, 108.3, 83.0, 82.3, 82.1, 81.6, 63.7, 44.7, 
37.0, 11.9. (EI, 70eV): m/z = 386(M+), 302(M+-3CO). FTIR (KBr): 3430(OH), 3170(CH), 
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3028(CH), 2959(CH), 2930(CH), 2822(CH), 2015(CO), 1932(CO), 1913(CO), 1688(C=O), 
1663(C=O), 1474, 1425, 1215 cm-1. Anal. Calcd for C16H15N2O6Mn: C, 49.76 ; H, 3.91 ; N, 
7.25%. Found: C, 49.82 ; H, 3.98 ; N, 7.25%. 
Compound 12 1H NMR (600 MHz, DMSO-d6 ):  = 10.98 (s, 1H, NH), 7.58 (d, JH,H = 7.8 
Hz, 1H, H6 uracil), 5.53 (d, JH,H = 7.8 Hz, 1H, H5 uracil), 5.43 (d, JH,H = 6.0 Hz, 1H, OH), 
5.09 (m 1H, Cp), 5.06 (m, 1H, Cp), 4.89 (pq, JH,H = 2.4Hz, 1H, Cp), 4.87 (pq, JH,H = 2.4Hz, 
1H, Cp), 4.22 (m, 1H, CH), 3.85 (m, 1H, CH2), 3.70 (m, 1H, CH2), 1.92 (m, 1H, CH2), 1.77 
(m, 1H, CH2). 
13C NMR (150 MHz, DMSO-d6):  = 225.5, 163.8, 150.9, 145.8, 110.7, 100.8, 
83.0, 82.4, 82.0, 81.7, 63.7, 45.0, 36.9. (EI, 70eV): m/z = 372(M+), 288(M+-3CO), 270(M+-
3CO-H2O). FTIR (KBr): 3377(OH), 3164(CH), 3049(CH), 2012(CO), 1936(CO), 1917(CO), 
1695(C=O), 1663(C=O), 1470, 1420, 1375, 1296 cm-1. Anal. Calcd for C15H13N2O6Mn: C, 
48.40 ; H, 3.52 ; N, 7.53%. Found: C, 48.16 ; H, 3.60 ; N, 7.37%. 
 
General procedure for the synthesis of cyrhetrene alkohols 13 and 14 
To a stirred THF solution (20 mL) containing either 6 or 7 (0.3 mmol)Na[BH4] (19 mg, 
0.5 mmol) was added in a single portion at ambient temperature. After 40 min of stirring, the 
reaction mixture was poured into 20 mL of water, extracted with chloroform (ca 40 mL), 
dried over MgSO4 and evaporated to dryness. The residue was subjected to column 
chromatography on SiO2 (eluent chloroform-methanol 50/5 (v/v)). Crystallization from 
chloroform-n-pentane gave alcohols 13 and 14 as colourless solids in an 82% yield (126 mg) 
and 79% yield (113 mg), respectively.  
Compound 13 1H NMR (600 MHz, DMSO-d6 ):  = 11.16 (s, 1H, NH), 7.45 (d, JH,H = 0.6 
Hz, 1H, H6 thymine), 5.72 (pd, JH,H = 2.4 Hz, 1H, Cp), 5.68 (pd, JH,H = 2.4 Hz, 1H, Cp), 5.54 
(m, 2H, Cp), 5.51 (d, JH,H = 6.0 Hz, 1H, OH), 4.31 (m, 1H, CH), 3.80 (m, 1H, CH2), 3.67 (m, 
1H, CH2), 1.93 (m, 1H, CH2), 1.75 (s, 3H, CH3), 1.73 (m, 1H, CH2). 
13C NMR (150 MHz, 
DMSO-d6):  = 195.4, 164.4, 151.0, 141.6, 115.4, 108.5, 84.3, 84.27, 84.23, 84.0, 63.6, 44.9, 
37.6, 12.0. MS (ESI): m/z = 541(M+Na+). FTIR (KBr): 3414(OH), 3107(CH), 3009(CH), 
2933(CH), 2832(CH), 2021(CO), 1942(CO), 1901(CO), 1674(C=O), 1671(C=O), 1484, 1429, 
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1369 cm-1. Anal. Calcd for C16H15N2O6Re: C, 37.13; H, 2.92; N, 5.41%. Found: C, 36.87; H, 
2.90; N, 5.35%. 
Compound 14 1H NMR (600 MHz, DMSO-d6 ):  = 11.17 (s, 1H, NH), 7.58 (d, JH,H = 7.8 
Hz, 1H, H6 uracil), 5.73 (pd, JH,H = 2.0 Hz, 1H, Cp), 5.69 (pd, JH,H = 2.0 Hz, 1H, Cp), 5.53 
(m, 4H, OH, Cp, H5 uracil), 4.31 (m, 1H, CH), 3.85 (m, 1H, CH2), 3.70 (m, 1H, CH2), 1.93 
(m, 1H, CH2), 1.74 (m, 1H, CH2). 
13C NMR (150 MHz, DMSO-d6):  =195.4, 163.8, 151.0, 
145.9, 115.3, 100.9, 84.3, 84.27, 84.25, 84.0, 63.6, 45.2, 37.5. (EI, 70eV): m/z = 504(M+), 
476(M+-CO), 448(M+-2CO). FTIR (KBr): 3379(OH), 3167(CH), 3117(CH), 3044(CH), 
2952(CH), 2927(CH), 2851(CH), 2018(CO), 1926(CO), 1901(CO), 1692(C=O), 1660(C=O) 
cm-1. Anal. Calcd for C15H13N2O6Re: C, 35.78; H, 2.60; N, 5.56%. Found: C, 36.01; H, 2.67; 
N. 5.54%. 
Synthesis of cymantrene alcohol (15) 
To a stirred solution of 5 (212 mg, 0.5 mmol) in THF (25 mL) Li[AlH4] (1 M) in THF (0.5 
mL, 0.5 mmol) was added at ambient temperature. The respective reaction mixture was stirred 
for 8 min and 25 mL of methanol-water 1/1 (v/v) were added. The organic phase was 
extracted with chloroform (ca 40 mL), dried over MgSO4 and evaporated to dryness. The 
residue was subjected to column chromatography on SiO2 (eluent chloroform-methanol 50/3 
(v/v)). Crystallization from chloroform-n-hexane ca. 1/2 (v/v) gave 15 as a yellow solid in an 
81% yield (395 mg). 
Compound 15 1H NMR (600 MHz, DMSO-d6 ):  = 8.13 (s, 1H, H2 adenine), 8.11 (s, 1H, 
H8 adenine), 7.13 (s, 2H, NH2), 5.58 (d, JH,H = 6.0 Hz, 1H, OH), 5.09 (s, 1H, Cp), 5.05 (s, 1H, 
Cp), 4.87 (pd, JH,H = 1.8 Hz, 1H, Cp), 4.85 (pd, JH,H = 1.8 Hz, 1H, Cp), 4.26 (m, 2H, CH2), 
4.18 (m, 1H, CH), 2.18 (m, 1H, CH2), 1.98 (m, 1H, CH2). 
13C NMR (150 MHz, DMSO-d6):  
= 225.4, 156.0, 152.4, 149.7, 141.1, 119.2, 110.5, 83.0, 82.4, 82.0, 81.5, 63.5, 40.0, 38.0. MS 
(EI, 70eV): m/z = 395 (M+), 311(M+-3CO). FTIR (KBr): 3370(OH), 3316, 3117, 2974(CH), 
2939(CH), 2018(CO), 1923(CO), 1651(NH), 1591(NH) cm-1. Anal. Calcd for 
C16H14N5O4Mn: C, 48.62 ; H, 3.57 ; N, 17.72%. Found: C, 48.68 ; H, 3.69 ; N, 17.56%. 
Synthesis of cymantrene-dppe derivative (16) 
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Alcohol 15 (150 mg, 0.38 mmol) and 1,2-bis(diphenylphosphino)ethane (167 mg, 0.42 
mmol) dissolved in anhydrous and argon-saturated THF (50 mL) were photolysed with a 200 
W high-pressure mercury lamp for 2 h. The solvent was evaporated to dryness. The residue 
was subjected to column chromatography on SiO2 (eluent chloroform-methanol 50/3 (v/v)). 
Crystallization from chloroform-n-hexane gave crude 16. Subsequently purification of 16 was 
conducted by normal phase HPLC with Luna 5u Silica (2) 100A, AXIA Packed 150 X 21.1 
mm preparative column. A mixture of dichloromethane (97%) and methanol (3%) and low 
pressure gradient with total flow pump 10 mL/min was used. Crystallization from n-hexane 
gave 16 as an orange solid in a 37% yield (104 mg). 
1H NMR (600 MHz, DMSO-d6 ):  = 8.10 (s, 1H, H2 adenine), 7.99 (s, 1H, H8 adenine), 
7.69(pt, JH,H = 6.6 Hz, 2H, Ph), 7.65(pt, JH,H = 6.6 Hz, 2H, Ph), 7.31(m, 12H, Ph), 7.13(s, 2H, 
NH2), 7.08(m, 4H, Ph), 4.97 (d, 
3JH,H = 6.0 Hz, 1H, OH), 4.46(s, 1H, Cp), 4.38(s, 1H, Cp), 
4.22 (m, 2H, CH2), 4.16(m, 1H, CH), 3.59(s, 1H, Cp), 3.30(s, 1H, Cp), 2.41(m, 2H, CH2 
dppe), 2.15(m, 2H, CH2 dppe), 2.10(m, 1H, CH2), 1.98(m, 1H, CH2).
 13C NMR (150 MHz, 
DMSO-d6):  = 233.1 (JP,C= 24 Hz), 156.0, 152.3, 149.6, 142.8, 140.7, 140.1-139.8 (m), 
132.5 (d, JP,C= 9 Hz), 132.4 (d, JP,C= 10 Hz), 130.8 (d, JP,C= 7 Hz), 129.0 (d, JP,C= 3 Hz), 
128.7 (d, JP,C= 7 Hz), 128.4 (d, JP,C= 3 Hz), 128.0 (d, JP,C= 6 Hz), 127.9 (d, JP,C= 7 Hz), 101.3, 
79.1, 78.6, 78.0, 75.6, 65.3, 40.3, 37.2, 29.7-29.4 (m). 31P{1H}NMR (243 MHz, DMSO-d6 ): 
 = 116.27 (d, JP,P = 15.3 Hz, dppe), 115.99 (d, JP,P = 15.3 Hz, dppe). MS (EI, 70eV): m/z = 
737(M+), 691(M+-CO-H2O). FTIR (KBr): 3376(OH), 3072, 3053, 2955(CH), 2927(CH), 
2857(CH), 1926, 1834(CO), 1635(NH), 1597(NH), 1480, 1435, 698 cm-1. Anal. Calcd for 
C40H38N5O2P2Mn: C, 65.13 ; H, 5.19 ; N, 9.49%. Found: C, 65.07 ; H, 5.32 ; N, 9.20%. 
Single-crystal X-ray structure of 5 
The crystal structure of 5 was solved by the Patterson method and refined on F2 by full-
matrix least-squares procedures using SHELXL.[37] All non-hydrogen atoms were refined 
with anisotropic displacement parameters. Carbon bonded hydrogen atoms were introduced in 
calculated positions with idealized geometry and constrained using a rigid body model with 
isotropic displacement parameters equal to 1.2 of the equivalent displacement parameters of 
the parent atoms. Positions amine NH hydrogen atoms were found on the Fourier difference 
map and refined. The molecular geometries were calculated by programs implemented in 
WinGX system.[38] A summary of relevant crystallographic data is given in Table S1.  
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Atoms’ coordinates and displacement parameters, and supplementary crystallographic 
data are deposited with Cambridge Crystallographic Data Centre under the number CCDC 
1485427. The data can be obtained free of charge via 
http://www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic 
Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033). 
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Graphical abstract 
 
 
Cymantrene, cyrhetrene and ferrocene nucleobase conjugates have been synthesised and 
studied by electrochemistry and DFT calculations. Some compounds exhibit significant 
activity against T. brucei a causative parasite of sleeping sickness.  
 
